Alzheimer's Disease Research
Alzheimer's disease (AD), the most common type of dementia, is an irreversible and progressive neurodegenerative disorder causing cognitive and functional impairment. It is characterized by formation of protein aggregates and progressive loss of neurons in the central nervous system (CNS). The symptoms of AD include short-term memory loss, confusion, irritability, aggression and mood swings, progressing to long-term memory deficit, withdrawal from social interactions and subsequently a loss in higher central functioning.
Alzheimer's Disease Research Products Targets
- Others (23)
- Cyclooxygenase (24)
- Complement (2)
- AMPA Receptor (45)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- NMDA Receptor (87)
- Kainate Receptor (22)
- Microtubule (19)
- DYRK (3)
- Cholinesterase (10)
- Autophagy (44)
- Antioxidant (19)
- Amyloid beta Peptide (28)
- Estrogen and Related Receptor (33)
- Glycogen Synthase Kinase 3 (20)
- gamma-Secretase (9)
Products for Alzheimer's Disease Research - Page 38
- Cat.No. Product Name Information/Activity
-
BCC4593
(-)-MK 801
(-)-Dizocilpine maleate ((-)-MK-801 maleate) is a less active (-)-enantiomer of Dizocilpine. (-)-Dizocilpine maleate is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with a Ki of 211.7 nM. (-)-Dizocilpine maleate has antidepressant effects.
-
BCC4014
(+)-MK 801 Maleate
Dizocilpine maleate (MK-801 maleate) is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
-
BCC5859
Norketamine hydrochloride
79499-59-5
-
BCC7895
NPEC-caged-D-AP5
1416943-27-5
-
BCC5644
Pentamidine isethionate
Pentamidine isethionate (MP-601205 isethionate) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine isethionate inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine isethionate is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine isethionate has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities.
-
BCC7308
PMPA (NMDA antagonist)
113919-36-1
-
BCC5918
PPDA
684283-16-7
-
BCC7309
PPPA
113190-92-4
-
BCC6292
QNZ 46
QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
-
BCC7129
Remacemide hydrochloride
111686-79-4


